IP in the deal room: The risks that bite before, during and after closing

Experts from Johnson & Johnson and Novartis took the stage at INTA to share the pitfalls lurking inside mergers, acquisitions and spin-offs and what in-house counsel can do about them.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Europe

Top law firms and individuals recognised in WIPR’s UK Patent Rankings 2026

28 August 2026 This year’s tables provide a guide to the best of the UK market for legal advice on the protection, enforcement and exploitation of patents.

Europe

UPC hands Occlutech second win against Chinese medtech company in a month

19 June 2026 The court overturns a decision granting the German-based company provisional measures and ordering a Chinese medtech rival to stop selling its device in four European countries.

Europe

Exclusive: ‘Cultural differences are an asset’ at the UPC

16 June 2026 In the second of a series of interviews with women judges at the pan-European court, Ulrike Voß talks to Sarah Speight about her career, her views on the court so far, and how more women could be encouraged to join the judiciary.

More features

G 1/25: EPO settles controversial patent description question

California votes for law to restrict use of genAI by lawyers

10x Genomics wins latest round in Parse patent dispute

Sun Pharma import ban back in force after Squires intervention

White & Case life sciences co-leader moves firms

‘Busiest’ US district patent judge swaps bench for private practice

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

Pinsents expands German patent practice with partner duo

IP in the deal room: The risks that bite before, during and after closing

More on this story

Editor's picks

Editor's picks

More features